Showing 3231-3240 of 6035 results for "".
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for the Treatment of Postoperative Inflammationhttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-the-treatment-of-postoperative-inflammation/2476198/Ocular Therapeutix announced the submission of a supplemental new drug application (NDA) to the FDA for Dextenza (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. The
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr
- Leica Biosystems Receives US Patent for RTF Extreme Speed Scanning Technologyhttps://modernod.com/news/leica-biosystems-receives-us-patent-for-rtf-extreme-speed-scanning-technology/2476211/Leica Biosystems announced that the US Patent Office has granted it a patent for RTF, its “Real-Time Focusing” technology (US patent 9,841,590). Leica says this will enable high volume, extremely fast line scanning of anatomic pathology slides. “RTF technology dramaticall
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana
- EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019https://modernod.com/news/eyepoint-pharmaceuticals-to-launch-dexycu-and-yutiq-in-first-quarter-of-2019/2476226/During a corporate update, EyePoint Pharmaceuticals executives said they expect to launch both Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of calendar 2019. “EyePoint has made significant progress in
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Lightmed Founder and Executive Chairman Gary Lee Reassumes CEO Rolehttps://modernod.com/news/lightmed-founder-and-executive-chairman-gary-lee-reassumes-ceo-role/2476234/Lightmed Corporation announced the reappointment of founder and Executive Chairman Gary Lee as Chief Executive Officer, effective immediately. Shlomo Alkalay has accomplished his CEO assignment and will return to his
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM
- Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese Markethttps://modernod.com/news/nicox-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-develop-and-commercialize-ncx-470-in-the-chinese-market/2479610/Nicox and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension
- RetinaLyze Receives Funding to Detect Diseases Such as Alzheimer’s Using AIhttps://modernod.com/news/retinalyze-receives-funding-to-detect-diseases-such-as-alzheimers-using-ai/2479612/RetinaLyze System A/S (Ltd.), a Denmark-based medical technology company that specializes in retinal imaging screening software, has received funding from The European Regional Development Fund (ERDF) and Central Denmark Region. The funding will be used to explore and develop novel AI-based solut